Imagine you attend a protest, like hundreds of thousands of Americans have since President Donald Trump began his second term. Perhaps it is a No Kings event, or a local ICE demonstration to protest ...

Cruise line stocks sailed higher on Monday as sentiment on the sector stayed positive due to the early reports of a strong Wave Season. Bookings and pricing are both higher than a year ago for the ...

AI is changing the way doctors diagnose health conditions and treat patients. There’s a lot of optimism about its potential for improving health outcomes. However, because AI requires massive amounts ...

Every time someone orders food online, checks exam results, or streams a video, new data is created and saved. Behind these activities are large databases that store millions of records. These ...

Every warfighting function depends on logistics, but sustainment has always faced a time-distance problem. Commanders maneuver in hours while logisticians plan in days. By the time a logistics ...

A developer for OpenAI and Oracle is facing stiff opposition to a proposed $1.4 billion transmission line for its Stargate project in Wisconsin. SAUKVILLE, Wisconsin — David Aversa spent months ...

AI copilots are incredibly intelligent and useful — but they can also be naive, gullible, and even dumb at times. A new one-click attack flow discovered by Varonis Threat Labs researchers underscores ...

Microsoft has fixed a vulnerability in its Copilot AI assistant that allowed hackers to pluck a host of sensitive user data with a single click on a legitimate URL. The hackers in this case were white ...

A new data center campus, known as "Project Eisenhower," is planned for Augusta near Fort Gordon. The development is projected to be operational by the second quarter of 2026. While representing a $2 ...

Adobe is updating its AI video-generation app, Firefly, with a new video editor that supports precise prompt-based edits, as well as adding new third-party models for image and video generation, ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...